Cart
sales@molnova.com
Amivantamab
CAS No. 2171511-58-1
Amivantamab( —— )
Catalog No. M36821 CAS No. 2171511-58-1
Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 439 | In Stock |
|
| 5MG | 748 | In Stock |
|
| 10MG | 1197 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAmivantamab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAmivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET).
-
DescriptionAmivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorc-Met/HGFR | EGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2171511-58-1
-
Formula Weight145.88 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402.??
molnova catalog
related products
-
NQ301
NQ301, an antithrombotic agent, inhibits collagen-challenged rabbit platelet aggregation (IC50: 10 mg/mL).
-
SAR125884 hydrochlor...
SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile(IC50=4.2 nM).
-
SAR125884
SAR125844 a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK) for intravenous administration.?(IC50 value of 4.2 nmol/L).
